Intriguingly, while the post-osimertinib MET/CEP7 ratios across multiple sampled tumors from patient LAT028 were similar to the pre-osimertinib MET/CEP ratio (none reached the >2.0 MET/CEP ratio threshold), all of the post-osimertinib LAT028 tumors exhibited strong, diffuse phospho-MET staining compared with negative phospho-MET IHC staining in the pre-osimertinib tumor biopsy suggesting additional factors may contribute to MET phosphorylation in this patient (Fig. 5A). The gene discussed is MET; the disease is neoplasm.